Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
1988 1
1991 3
1993 1
1994 1
1995 5
1996 7
1997 5
1998 9
1999 7
2000 8
2001 10
2002 7
2003 10
2004 12
2005 12
2006 11
2007 4
2008 11
2009 5
2010 16
2011 13
2012 16
2013 11
2014 3
2015 9
2016 6
2017 6
2018 8
2019 7
2020 6
2021 2
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

220 results
Results by year
Filters applied: . Clear all
Page 1
AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB. Ip CW, et al. Among authors: brotchie jm. Acta Neuropathol Commun. 2017 Feb 1;5(1):11. doi: 10.1186/s40478-017-0416-x. Acta Neuropathol Commun. 2017. PMID: 28143577 Free PMC article.
Levodopa-induced dyskinesias.
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Fabbrini G, et al. Among authors: brotchie jm. Mov Disord. 2007 Jul 30;22(10):1379-1389. doi: 10.1002/mds.21475. Mov Disord. 2007. PMID: 17427940 Review.
Exosome markers of LRRK2 kinase inhibition.
Wang S, Kelly K, Brotchie JM, Koprich JB, West AB. Wang S, et al. Among authors: brotchie jm. NPJ Parkinsons Dis. 2020 Nov 13;6(1):32. doi: 10.1038/s41531-020-00138-7. NPJ Parkinsons Dis. 2020. PMID: 33298972 Free PMC article.
Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
Karikari AA, McFleder RL, Ribechini E, Blum R, Bruttel V, Knorr S, Gehmeyr M, Volkmann J, Brotchie JM, Ahsan F, Haack B, Monoranu CM, Keber U, Yeghiazaryan R, Pagenstecher A, Heckel T, Bischler T, Wischhusen J, Koprich JB, Lutz MB, Ip CW. Karikari AA, et al. Among authors: brotchie jm. Brain Behav Immun. 2022 Mar;101:194-210. doi: 10.1016/j.bbi.2022.01.007. Epub 2022 Jan 12. Brain Behav Immun. 2022. PMID: 35032575 Free article.
New approaches to therapy.
Brotchie J, Jenner P. Brotchie J, et al. Int Rev Neurobiol. 2011;98:123-50. doi: 10.1016/B978-0-12-381328-2.00005-5. Int Rev Neurobiol. 2011. PMID: 21907085 Review.
The serotonergic system in Parkinson's disease.
Huot P, Fox SH, Brotchie JM. Huot P, et al. Among authors: brotchie jm. Prog Neurobiol. 2011 Oct;95(2):163-212. doi: 10.1016/j.pneurobio.2011.08.004. Epub 2011 Aug 22. Prog Neurobiol. 2011. PMID: 21878363 Review.
Monoamine reuptake inhibitors in Parkinson's disease.
Huot P, Fox SH, Brotchie JM. Huot P, et al. Among authors: brotchie jm. Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25. Parkinsons Dis. 2015. PMID: 25810948 Free PMC article. Review.
Non-steric-zipper models for pathogenic α-synuclein conformers.
Schuman B, Won A, Brand-Arzamendi K, Koprich JB, Wen XY, Howson PA, Brotchie JM, Yip CM. Schuman B, et al. Among authors: brotchie jm. APL Bioeng. 2018 May 1;2(2):026105. doi: 10.1063/1.5023460. eCollection 2018 Jun. APL Bioeng. 2018. PMID: 31069302 Free PMC article.
220 results